Clinical trial
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's…
NCT02245737 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT02245737 |
|---|---|
| Title | An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease |
| Official title | A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study) |
| Acronym | AMARANTH |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer´s Disease |
| Intervention type | Drug |
| Interventions | Lanabecestat, Placebo |
| Enrollment | 2,218 |
| Start date | Sep 30, 2014 |
| Primary completion | Oct 4, 2018 |
| Completion | Oct 4, 2018 |
| First posted | Sep 22, 2014 |
| Last update posted | Dec 3, 2019 |
| Countries | Australia, Belgium, Canada, France, Germany, Hungary, Italy, Japan, Poland, Puerto Rico, Romania, South Korea and 3 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: